Cancer Research

Pandemic impact on cancer research and researchers revealed

30 November 2020

Cancer researchers fear advances for patients could be delayed by almost a year and a half because of the effects of the COVID-19 pandemic, a new survey reveals. Scientists at The Institute of Cancer Research, London, told the survey that their own research advances would be pushed back by an average of six months by […]

World-first skin cancer therapy aims to help transplant patients

19 November 2020

A new drug had been developed which can be applied to the skin to help prevent organ transplant recipients from developing harmful skin cancers. The world-first treatment being developed at The University of Queensland is said to be the only drug of its type that could prevent the incidence of skin cancers for transplant patients. […]

Antidepressant helps to inhibit growth of cancer cells in lab animals

19 November 2020

New research has shown that the antidepressant sertraline helps to inhibit the growth of cancer cells. The substance acts on a metabolic addiction that allows different types of cancer to grow. This is shown by a study on cell cultures and lab animals performed by various research labs of KU Leuven. Their findings were published […]

STORM Therapeutics uses Evotec platform to push oncology project towards clinical studies

17 November 2020

STORM Therapeutics will use INDiGO, Evotec’s integrated, accelerated IND-enabling platform, to progress its STC-15 towards an IND application in 2021. STORM, a biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has selected STC-15 as a first-in-class development candidate. STORM discovered STC-15, an orally bioavailable, small molecule inhibitor of […]

Merck’s acquisition of VelosBio will boost oncology push

12 November 2020

Merck (known as MSD outside the United States and Canada), is paying  $2.75 billion for VelosBio, a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is currently being evaluated in a Phase I […]

Next-generation immunotherapy now entering early phase clinical trials

10 November 2020

Cancer Research UK scientists have invented a new experimental drug that aims to harness the full power of the body’s own immune system, launching a two-pronged response against cancer, according to a study published in Nature Cancer. In the study, partly funded by Cancer Research UK, the new immunotherapy drug, which targets suppressive ‘regulatory’ immune […]

Partnership will progress targeted cancer immune therapy drug discovery

9 November 2020

APEIRON Biologics, a biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery. Under the terms of the agreement, Domainex, an integrated drug discovery research service […]

Scientists engineer new cancer immunotherapy to train immune system in cancer fight

2 November 2020

A new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumour cells through the use of nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component, according to a study published in Cell. This nanobiologic immunotherapy […]

Cancer Research UK collaboration will identify oncology innovation

2 November 2020

The national programme, to develop and progress start-up oncology projects, is being launched by Bruntwood SciTech at Alderley Park with funding from Innovate UK and Cancer Research UK A collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies will identify oncology innovations and leverage their combined insight and expertise to nurture them […]

Mission Bio launches single-cell multi-omics system for precision cancer therapies

30 October 2020

Mission Bio has launched the Tapestri Single-cell Multi-omics Solution – a comprehensive single-cell multi-omics platform. With a new instrument, single-cell multi-omics reagent kits, TotalSeq-D antibody content from BioLegend, and visualisation software, the package provides layered insight into multiple analytes across all blood cancers, reducing drug development time and cost by at least half. The company […]

Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free